TY - JOUR
T1 - Antenatal corticosteroid treatment in singleton, small-for-gestational-age infants born at 24–31 weeks’ gestation
T2 - a population-based study
AU - Riskin-Mashiah, S.
AU - Riskin, A.
AU - Bader, D.
AU - Kugelman, A.
AU - Boyko, V.
AU - Lerner-Geva, L.
AU - Reichman, B.
N1 - Publisher Copyright: © 2016 Royal College of Obstetricians and Gynaecologists
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Objective: To assess the impact of antenatal corticosteroid therapy on mortality and severe morbidities in preterm, small-for-gestational-age (SGA) neonates compared with preterm non-SGA neonates. Design: Population-based study. Setting/population: Israel National Very Low Birth Weight infant database from 1995–2012. Methods: Singleton infants of 24–31 weeks’ gestation, without major malformations. Antenatal corticosteroids were considered either any treatment or no treatment. Main outcome measures: Univariate and multivariable logistic regression analyses were performed to assess the effect of antenatal corticosteroids on neonatal mortality and a composite adverse outcome of mortality or severe neonatal morbidity. Results: Among the 10 887 study infants, 1771 were SGA. Of these, 70.4% of SGA and 66.7% of non-SGA neonates were exposed to antenatal corticosteroids. Among SGA neonates, antenatal corticosteroids were associated with decreased mortality (32.2 versus 19.3%, P < 0.0001) and composite adverse outcome (54.1 versus 43.4%, P < 0.0001), similar to the effect in non-SGA neonates (mortality 26.7 versus 12.2%, P < 0.0001; composite outcome 50.5 versus 34.6%, P < 0.0001). Multivariable logistic regression analyses demonstrated a 50% reduction in mortality risk among SGA and 57% reduction in non-SGA neonates exposed to corticosteroids [OR = 0.50, 95% confidence interval (95% CI) 0.39–0.64 and OR = 0.43, 95% CI 0.38–0.47, respectively], P-value for interaction = 0.08. Composite adverse outcome risk was significantly reduced in SGA (OR = 0.67, 95% CI 0.54–0.83) and non-SGA infants (OR = 0.57, 95% CI 0.52–0.63), P-value for interaction = 0.04. Conclusions: Antenatal corticosteroids significantly reduced mortality and severe morbidities among preterm SGA neonates, with slightly a less pronounced effect compared with non-SGA preterm infants. Antenatal corticosteroids should be given to fetuses suspected of intrauterine growth retardation, at risk for preterm delivery, in order to improve perinatal outcome. Tweetable abstract: Antenatal steroids reduced mortality and severe morbidities among singleton, preterm SGA neonates.
AB - Objective: To assess the impact of antenatal corticosteroid therapy on mortality and severe morbidities in preterm, small-for-gestational-age (SGA) neonates compared with preterm non-SGA neonates. Design: Population-based study. Setting/population: Israel National Very Low Birth Weight infant database from 1995–2012. Methods: Singleton infants of 24–31 weeks’ gestation, without major malformations. Antenatal corticosteroids were considered either any treatment or no treatment. Main outcome measures: Univariate and multivariable logistic regression analyses were performed to assess the effect of antenatal corticosteroids on neonatal mortality and a composite adverse outcome of mortality or severe neonatal morbidity. Results: Among the 10 887 study infants, 1771 were SGA. Of these, 70.4% of SGA and 66.7% of non-SGA neonates were exposed to antenatal corticosteroids. Among SGA neonates, antenatal corticosteroids were associated with decreased mortality (32.2 versus 19.3%, P < 0.0001) and composite adverse outcome (54.1 versus 43.4%, P < 0.0001), similar to the effect in non-SGA neonates (mortality 26.7 versus 12.2%, P < 0.0001; composite outcome 50.5 versus 34.6%, P < 0.0001). Multivariable logistic regression analyses demonstrated a 50% reduction in mortality risk among SGA and 57% reduction in non-SGA neonates exposed to corticosteroids [OR = 0.50, 95% confidence interval (95% CI) 0.39–0.64 and OR = 0.43, 95% CI 0.38–0.47, respectively], P-value for interaction = 0.08. Composite adverse outcome risk was significantly reduced in SGA (OR = 0.67, 95% CI 0.54–0.83) and non-SGA infants (OR = 0.57, 95% CI 0.52–0.63), P-value for interaction = 0.04. Conclusions: Antenatal corticosteroids significantly reduced mortality and severe morbidities among preterm SGA neonates, with slightly a less pronounced effect compared with non-SGA preterm infants. Antenatal corticosteroids should be given to fetuses suspected of intrauterine growth retardation, at risk for preterm delivery, in order to improve perinatal outcome. Tweetable abstract: Antenatal steroids reduced mortality and severe morbidities among singleton, preterm SGA neonates.
KW - Adverse perinatal outcome
KW - antenatal corticosteroids
KW - intrauterine growth restriction
KW - preterm delivery
KW - small for gestational age
UR - http://www.scopus.com/inward/record.url?scp=84988405294&partnerID=8YFLogxK
U2 - 10.1111/1471-0528.13723
DO - 10.1111/1471-0528.13723
M3 - مقالة
C2 - 26552861
SN - 1470-0328
VL - 123
SP - 1779
EP - 1786
JO - BJOG: An International Journal of Obstetrics and Gynaecology
JF - BJOG: An International Journal of Obstetrics and Gynaecology
IS - 11
ER -